Baird Reiterates a 'Outperform' on Regeneron Pharma (REGN); Bullish Thesis Intact

Baird reiterates a 'Outperform' on Regeneron Pharma (NASDAQ: REGN) price target of $125.00.

Baird analyst said, "After three days on the road with REGN management, we come away increasingly confident in our bullish stance on the stock. With shares having pulled back ~5% this week (NBI flat); we are buyers on recent weakness as we continue to like the stock for the near-term Eylea ramp and an increasingly attractive late-stage pipeline. While we expect volatility in the stock to continue near term, we ultimately see shares working higher into the $125 area."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $116.13 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform